Moreau P - Search Results

1

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial.

Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F, Sotto JJ, Guilhot F, Marit G, Doyen C, Jaubert J, Fuzibet JG, François S, Benboubker L, Monconduit M, Voillat L, Macro M, Berthou C, Dorvaux V, Pignon B, Rio B, Matthes T, Casassus P, Caillot D, Najman N, Grosbois B, Bataille R, Harousseau JL; Intergroupe Francophone du Myélome. Moreau P, et al. Blood. 2002 Feb 1;99(3):731-5. doi: 10.1182/blood.v99.3.731. Blood. 2002. PMID: 11806971 Free article. Clinical Trial.

2

Tandem high-dose therapy followed by autologous stem-cell transplantation for refractory or relapsed high grade non-Hodgkin's lymphoma with poor prognosis factors: a prospective pilot study.

Le Gouill S, Moreau P, Morineau N, Harousseau JL, Milpied N. Le Gouill S, et al. Among authors: moreau p. Haematologica. 2002 Mar;87(3):333-4. Haematologica. 2002. PMID: 11869953

3

Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy.

Moreau P, Facon T, Leleu X, Morineau N, Huyghe P, Harousseau JL, Bataille R, Avet-Loiseau H; Intergroupe Francophone du Myélome. Moreau P, et al. Blood. 2002 Sep 1;100(5):1579-83. doi: 10.1182/blood-2002-03-0749. Blood. 2002. PMID: 12176874 Free article.

4

Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).

Yakoub-Agha I, Attal M, Dumontet C, Delannoy V, Moreau P, Berthou C, Lamy T, Grosbois B, Dauriac C, Dorvaux V, Bay JO, Monconduit M, Harousseau JL, Duguet C, Duhamel A, Facon T. Yakoub-Agha I, et al. Among authors: moreau p. Hematol J. 2002;3(4):185-92. doi: 10.1038/sj.thj.6200175. Hematol J. 2002. PMID: 12189564

5

Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia.

Solary E, Drenou B, Campos L, de Crémoux P, Mugneret F, Moreau P, Lioure B, Falkenrodt A, Witz B, Bernard M, Hunault-Berger M, Delain M, Fernandes J, Mounier C, Guilhot F, Garnache F, Berthou C, Kara-Slimane F, Harousseau JL; Groupe Ouest Est Leucémies Aiguës Myéloblastiques. Solary E, et al. Among authors: moreau p. Blood. 2003 Aug 15;102(4):1202-10. doi: 10.1182/blood-2002-11-3419. Epub 2003 Mar 27. Blood. 2003. PMID: 12663440 Free article. Clinical Trial.

6

CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma.

Robillard N, Avet-Loiseau H, Garand R, Moreau P, Pineau D, Rapp MJ, Harousseau JL, Bataille R. Robillard N, et al. Among authors: moreau p. Blood. 2003 Aug 1;102(3):1070-1. doi: 10.1182/blood-2002-11-3333. Epub 2003 Apr 17. Blood. 2003. PMID: 12702507 Free article.

7

Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma.

Moreau P, Robillard N, Avet-Loiseau H, Pineau D, Morineau N, Milpied N, Harousseau JL, Bataille R. Moreau P, et al. Haematologica. 2004 May;89(5):547-51. Haematologica. 2004. PMID: 15136217

8

Disseminated mucormycosis associated with invasive pulmonary aspergillosis in a patient treated for post-transplant high-grade non-Hodgkin's lymphoma.

Blin N, Morineau N, Gaillard F, Morin O, Milpied N, Harousseau JL, Moreau P. Blin N, et al. Among authors: moreau p. Leuk Lymphoma. 2004 Oct;45(10):2161-3. doi: 10.1080/10428190410001700803. Leuk Lymphoma. 2004. PMID: 15370266

9

Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required.

Vigouroux S, Morin O, Moreau P, Méchinaud F, Morineau N, Mahé B, Chevallier P, Guillaume T, Dubruille V, Harousseau JL, Milpied N. Vigouroux S, et al. Among authors: moreau p. Clin Infect Dis. 2005 Feb 15;40(4):e35-7. doi: 10.1086/427752. Epub 2005 Jan 25. Clin Infect Dis. 2005. PMID: 15712069

10

CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity.

Bataille R, Robillard N, Avet-Loiseau H, Harousseau JL, Moreau P. Bataille R, et al. Among authors: moreau p. Haematologica. 2005 May;90(5):706-7. Haematologica. 2005. PMID: 15921396

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,679 results

Search Page